{
    "clinical_study": {
        "@rank": "136107", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "arm_group_type": "Experimental", 
                "description": "Group 1"
            }, 
            {
                "arm_group_label": "Group 2", 
                "arm_group_type": "Experimental", 
                "description": "Group 2"
            }, 
            {
                "arm_group_label": "Group 3", 
                "arm_group_type": "Experimental", 
                "description": "Group 3"
            }, 
            {
                "arm_group_label": "Group 4", 
                "arm_group_type": "Experimental", 
                "description": "Group 4"
            }, 
            {
                "arm_group_label": "Group 5", 
                "arm_group_type": "Experimental", 
                "description": "Group 5"
            }
        ], 
        "brief_summary": {
            "textblock": "This multi-center study is designed to describe natural history of disease, treatment and\n      health care products in physician-diagnosed COPD patients who require adding daily\n      maintenance therapy in real world."
        }, 
        "brief_title": "A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "COPD", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willing and able to provide informed consent\n\n          -  Physician-diagnosis of COPD\n\n          -  COPD patients requiring long-acting bronchodilator treatment\n\n          -  Patients with spirometry available at baseline\n\n        Exclusion Criteria:\n\n          -  Patients who have a diagnosis of asthma.\n\n          -  Patients who had been hospitalized for a COPD exacerbation in the 4 weeks prior to\n             Visit 1.\n\n          -  Current clinical diagnosis of other chronic respiratory illnesses\n\n          -  Concurrent participation in a clinical trial or use of an investigational drug.\n\n          -  Active malignancy or history of malignancy of any organ system\n\n          -  Pregnant or nursing (lactating) women\n\n          -  Women of child-bearing potential with no contraception Other protocol-defined\n             inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794780", 
            "org_study_id": "CQAB149BCN01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group 1", 
                "description": "LABA based treatment: indacaterol", 
                "intervention_name": "LABA based treatment: indacaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "LAMA based treatment: tiotropium", 
                "intervention_name": "LAMA based treatment: tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 3", 
                "description": "LABA/ICS based treatment: salmeterol/fluticasone", 
                "intervention_name": "LABA/ICS based treatment: salmeterol/fluticasone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 4", 
                "description": "LABA/ICS based treatment: budesonide/formoterol", 
                "intervention_name": "LABA/ICS based treatment: budesonide/formoterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Group 5", 
                "description": "theophylline based treatment", 
                "intervention_name": "theophylline based treatment", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bronchodilator Agents", 
                "Theophylline", 
                "Budesonide", 
                "Formoterol", 
                "Salmeterol", 
                "Fluticasone", 
                "Tiotropium", 
                "Symbicort"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100730"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "5", 
        "official_title": "A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function.", 
            "measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", 
            "safety_issue": "No", 
            "time_frame": "Baseline,3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794780"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Forced expiratory volume in 1 second (FEV1) is the amount of air that can be exhaled in one second. A positive change from baseline in FEV1 indicates improvement in lung function.", 
                "measure": "Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "Baseline,12 months"
            }, 
            {
                "description": "Number of COPD exacerbations evaluated over 12 months", 
                "measure": "COPD exacerbation", 
                "safety_issue": "No", 
                "time_frame": "Baseline,12 months"
            }, 
            {
                "description": "mMRC, uses a simple grading system to assess a patient's level of dyspnea. The mMRC scale is scored from 0 (less severe) to 4 (severe).", 
                "measure": "Questionnaire MMRC", 
                "safety_issue": "No", 
                "time_frame": "Baseline,3,6,9,12 months"
            }, 
            {
                "description": "CAT is designed to measure the impact of COPD on a person's life, and how this changes over time.The CAT score is based on eight domains with each domain scored from 0 (major improvement) to 5 (major deterioration).", 
                "measure": "Questionnaire CAT", 
                "safety_issue": "No", 
                "time_frame": "Baseline,3,6,9,12 months"
            }, 
            {
                "description": "Transition Dyspnea Index (TDI) captures changes from baseline. The TDI score is based on three domains with each domain scored from -3 (major deterioration) to +3 (major improvement), to give an overall score of -9 to +9, a negative score indicating a deterioration from baseline. A TDI focal score of 1 is considered to be a clinically significant improvement from baseline.", 
                "measure": "Questionnaire TDI", 
                "safety_issue": "No", 
                "time_frame": "Baseline,3,6,9,12 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}